NANO-X IMAGING (NNOX) Stock News

Nanox (NNOX) reported Q2 2026 results with revenue of $4.2 million, up 37% year over year.

The quarter’s revenue came from $3.0 million in teleradiology, $1.0 million in AI and software solutions, and $0.2 million in imaging systems and OEM services. Q2 GAAP gross loss margin was (1,051%), while non-GAAP gross loss margin improved to (13%) from (21%) a year earlier. Adjusted EBITDA loss was $11.3 million, and GAAP net loss was $55.5 million, driven mainly by a $40.7 million non-cash impairment to AI-related intangible assets, leaving that asset group at $1.9 million.

Cash and cash equivalents were $31.4 million on June 30, 2026, and the company raised a further $8.5 million post quarter-end. Operationally, Nanox expanded U.S. distribution to ten partners, began patient scanning and reimbursement at its first Nanox Imaging Network site, grew Nanox Health IT with over 20 new projects, and initiated a Korea restructuring, including a 67% workforce reduction, expected to yield about $2 million in annual savings from 2027.

Nano-X Imaging (NNOX) announced that its U.S. subsidiary Nanox Impact has signed a distribution agreement with New England-based Associated X-Ray Imaging to expand deployment of the FDA-cleared Nanox.ARC system across the region.

Associated X-Ray Imaging will market, distribute, and support the Nanox.ARC, a multisource 3D digital tomosynthesis system, using its established sales and service infrastructure. The collaboration targets broader access to advanced 3D imaging in outpatient and community-based clinical settings and fits into Nanox’s U.S. channel partner strategy to build a diversified regional distribution network.

Nanox (Nasdaq: NNOX) announced it will release its financial results for the quarter ended June 30, 2026 before market open on Monday, September 9, 2026. Following the release, CEO and Acting Chairman Erez Meltzer and CFO Guy Nathanzon will host a conference call and live webcast at 8:30 a.m. ET, with access details and webcast link available via online registration and the Investor Relations section of the Nanox website under Events and Presentations.

Nanox (NASDAQ: NNOX) announced that its subsidiary Nanox AI has entered an exclusive three-year sales reseller agreement with Vertec Scientific for the commercialization of its AI-based bone solution HealthOST in the United Kingdom. Vertec receives exclusive rights to market and resell HealthOST, contingent on meeting minimum annual license commitments.

HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to support assessment of spine-related musculoskeletal disease, including osteoporosis. According to Nanox, the solution integrates with existing PACS, requires no additional imaging or radiation, and was recommended by NICE in November 2025 for NHS use to aid opportunistic detection of vertebral fragility fractures.

Nanox.AI (NASDAQ: NNOX), a subsidiary of Nano-X Imaging, announced it has optimized its on-premise medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. The framework supports AI applications running on edge devices inside healthcare facilities, allowing organizations to evaluate and deploy CT imaging AI while keeping imaging data within their own infrastructure.

Nanox.AI solutions analyze routine CT scans to help identify findings correlated with chronic conditions related to cardiac, liver and bone health, aiming to support preventive care management. According to the company, the optimized framework ran inference successfully and efficiently on Intel Core Ultra-class hardware, highlighting suitability for local, on-premise AI processing and reduced dependence on cloud connectivity.

Nano-X Imaging (Nasdaq: NNOX) entered into a securities purchase agreement with a single long-term institutional investor for a registered direct offering priced at-the-market under Nasdaq rules. The investor will purchase 8,000,000 Ordinary Shares (or prefunded warrants in lieu thereof) and warrants to buy up to 8,000,000 Ordinary Shares at a combined price of $1.00 per share and accompanying warrant.

The warrants have a $1.15 exercise price, become exercisable six months after issuance, and expire five years from closing. Closing is expected on or about August 7, 2026, with expected gross proceeds of approximately $8 million before fees. According to Nano-X, net proceeds will be used for working capital and general corporate purposes, with A.G.P./Alliance Global Partners acting as sole placement agent.

Nanox (NASDAQ:NNOX) will present new clinical data on its Nanox.AI cardiac solution HealthCCSng at the SCCT 2026 meeting in San Diego, July 9-12, 2026.

Highlights include initial multi-site AI INFORM trial results, a coronary calcium agreement analysis, and a sponsored session on aortic valve calcification.

Nanox (NASDAQ:NNOX) reported Q1 2026 revenue of $4.3M, up from $2.8M a year earlier, driven mainly by teleradiology and AI/software solutions. GAAP gross loss was $2.6M, with non-GAAP gross loss of $0.2M. Net loss reached $14.3M. Cash and deposits fell to $44.2M, with negative operating cash flow of $14.0M and an estimated $27M cash (net of a short-term loan) at release date, leading management to state there is substantial doubt about continuing as a going concern. The company withdrew its 2026 revenue target, will stop giving annual revenue guidance, has about 40 systems in deployment and distribution agreements for about 360 Capex systems over 2–3 years.

Nanox (Nasdaq:NNOX) will report first quarter 2026 financial results for the period ended March 31, 2026, before market open on June 25, 2026.

Management will host a conference call and live webcast at 8:30 a.m. ET to review results and provide a business update.